Anixa Biosciences Announces University of Maryland School of Medicine to Join Cchekâ„¢ Prostate Cancer Study
Anixa Biosciences Announces University of Maryland School of Medicine to Join Cchekâ„¢ Prostate Cancer Study |
[23-September-2019] |
SAN JOSE, Calif., Sept. 23, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that Mohummad Siddiqui, MD, Associate Professor of Surgery at the University of Maryland School of Medicine (UMSOM) has joined its ongoing prostate cancer Cchekâ„¢ study.
UMSOM is one of several sites across the United States participating in this study. Study enrollment will be led by Dr. Mohummad Siddiqui, who is also the Director of Urologic Oncology and Robotic Surgery and Chief of Urology at the Baltimore VA Medical Center. "We are pleased to be working with Dr. Siddiqui and the University of Maryland School of Medicine to further develop our artificial intelligence based prostate cancer diagnostic test," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "Significant progress has been made in our efforts to advance the Cchekâ„¢ Prostate Cancer Confirmation test toward commercial launch later this year. We believe the Cchekâ„¢ early cancer detection platform will make a great impact on patient care, and we are pleased by the continued additions to our team of collaboration partners." About Anixa Biosciences, Inc. About the University of Maryland School of Medicine Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Anixa contact: Tiberend Strategic Advisors, Inc. Sharen Tilman (Investors) Johanna Bennett (Media) View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-university-of-maryland-school-of-medicine-to-join-cchek-prostate-cancer-study-300922712.html SOURCE Anixa Biosciences, Inc. | ||
Company Codes: NASDAQ-NMS:ANIX |
© 2019 PR Newswire. All Rights Reserved.